IN8bio Reports Fourth Quarter and Full-Year 2021 Financial R

All patients treated with INB-200, in clinical development for the treatment of glioblastoma multiforme , have shown a well-tolerated safety profile and longer than anticipated progression free... | March 17, 2022

Related Keywords

United States , Czech Republic , Prague , Praha , Hlavníesto , Washington , San Francisco , California , American , Kate Rochlin , Robert Flamm , Trishna Goswami , Anita Hjelmeland , David Buck , Anticancer Therapies Congress , Company Contact , Society For Immunotherapy Conference , Burns Mcclellan Inc , American Association Of Cancer Research , Research Development , University Of Alabama At Birmingham , Nasdaq , Exchange Commission , European Society For Blood , Company Vice , American Society Of Gene , International Society For Cell Gene Therapy , European Society For Medical Oncology , Globenewswire Inc , Chief Executive Officer , Scientific Reports , Nature Portfolio , Annual Meeting , Chief Medical , Chief Operating , Vice President , Cell Therapy , Expected Upcoming Scientific Presentations , Medical Oncology , Targeted Anticancer Therapies Congress , Marrow Transplantation , Cancer Research , Gene Therapy , Shelf Cell Therapies , Beyondt Cells , Education Session , Next Generation , Full Year , Private Securities Litigation Reform Act , Quarterly Report , Convertible Preferred Stock , Stockholder Equity , In8bio , Nc Stock Exchange , News , Information , Press Release , Wall , Patients , Reated , Ith , N , Linical , Development , Or , The , Treatment , F , Glioblastoma , Multiforme , Wave , Hown , Safety , Profile , End , Longer , Han , Nticipated , Rogression Inab Us45674e1091 ,